Most people tolerate them well, experiencing only mild side effects such as temporary soreness at the injection site or mild headaches
In the three and a half years since the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ~770 million (M) infections and ~7 M related deaths have been reported [1]
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
J Mater Chem A 7(36):2084020846 He Q, Ding L, Raheem A, Guo Q, Gong Y, Yu G (2021) Kinetics comparison and insight into structure-performance correlation for leached biochar gasification
.png.jpg)
